nCPAP alone

DEVICE2 trials

Sponsors

Windtree Therapeutics

Conditions

Respiratory Distress Syndrome

Phase 2

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

CompletedNCT02074059

Windtree TherapeuticsRespiratory Distress Syndrome

Start: 2014-02-28End: 2015-11-30Updated: 2017-04-21

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

TerminatedNCT02528318

Windtree TherapeuticsRespiratory Distress Syndrome

Start: 2015-08-31End: 2017-08-11Updated: 2019-07-23